Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 133

The DOI matches its Crossref record.

Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors

Kratochwil, Clemens, Combs, Stephanie E., Leotta, Karin, Afshar-Oromieh, Ali, Rieken, Stefan, Debus, Jürgen, Haberkorn, Uwe, Giesel, Frederik L. · 2014 · Neuro-Oncology

Abstract

BACKGROUND: Both (18)F-fluorodihydroxyphenylalanine ((18)F-DOPA) and (18)F-fluoroethyltyrosine ((18)F-FET) have already been used successfully for imaging of brain tumors. The aim of this study was to evaluate differences between these 2 promising tracers to determine the consequences for imaging protocols and the interpretation of findings. METHODS: Forty minutes of dynamic PET imaging were performed on 2 consecutive days with both (18)F-DOPA and (18)F-FET in patients with recurrent low-grade astrocytoma (n = 8) or high-grade glioblastoma (n = 8). Time-activity-curves (TACs), standardized uptake values (SUVs) and compartment modeling of both tracers were analyzed, respectively. RESULTS: The TAC of DOPA-PET peaked at 8 minutes p.i. with SUV 5.23 in high-grade gliomas and 10 minutes p.i. with SUV 4.92 in low-grade gliomas. FET-PET peaked at 9 minutes p.i. with SUV 3.17 in high-grade gliomas and 40 minutes p.i. with SUV 3.24 in low-grade gliomas. Neglecting the specific uptake of DOPA into the striatum, the tumor-to-brain and tumor-to-blood ratios were higher for DOPA-PET. Kinetic modeling demonstrated a high flow constant k1 (mL/ccm/min), representing cellular internalization through AS-transporters, for DOPA in both high-grade (k1 = 0.59) and low-grade (k1 = 0.55) tumors, while lower absolute values and a relevant dependency from tumor-grading (high-grade k1 = 0.43; low-grade k1 = 0.33) were observed with FET. CONCLUSIONS: DOPA-PET demonstrates superior contrast ratios for lesions outside the striatum, but SUVs do not correlate with grading. FET-PET can provide additional information on tumor grading and benefits from lower striatal uptake but presents lower contrast ratios and requires prolonged imaging if histology is not available in advance due to a more variable time-to-peak.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/not199

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 28

  1. Langen, 1991, Brain and brain tumor uptake of L-3-[123I]iodo-alpha-methyl tyrosine: competition with natural L-amino acids, J Nucl Med, 32, 1225
  2. Derlon, 1989, [11C]L-methionine uptake in gliomas, Neurosurgery, 25, 720, 10.1227/00006123-198911000-00006 · doi:10.1227/00006123-198911000-00006
  3. Langen, 1997, 3-[123I]iodo-alpha-methyltyrosine and [methyl-11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET, J Nucl Med, 38, 517
  4. Henze, 2004, PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis, J Nucl Med, 45, 579
  5. Heiss, 1996, F-Dopa as an amino acid tracer to detect brain tumors, J Nucl Med, 37, 1180
  6. Pauleit, 2005, O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas, Brain, 128, 678, 10.1093/brain/awh399 · DOI · Paper page
  7. Minn, 2009, 18F-FDOPA: a multiple-target molecule, J Nucl Med, 50, 1915, 10.2967/jnumed.109.065664 · DOI
  8. Youland, 2013, The role of LAT1 in (18)F-DOPA uptake in malignant gliomas, J Neurooncol, 111, 11, 10.1007/s11060-012-0986-1 · DOI
  9. Wester, 1999, Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging, J Nucl Med, 40, 205
  10. Heiss, 1999, Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo, J Nucl Med, 40, 1367
  11. Langen, 2006, O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications, Nucl Med Biol, 33, 287, 10.1016/j.nucmedbio.2006.01.002 · DOI · Paper page
  12. Combs, 2010, Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial, BMC Cancer, 10, 478, 10.1186/1471-2407-10-478 · DOI
  13. Combs, 2010, Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial, BMC Cancer, 10, 533, 10.1186/1471-2407-10-533 · DOI
  14. Hoffman, 1992, The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography, J Nucl Med, 33, 1472
  15. Endres, 2004, Time profile of cerebral [18F]6-fluoro-L-DOPA metabolites in nonhuman primate: implications for the kinetics of therapeutic L-DOPA, Front Biosci, 9, 505, 10.2741/1224 · doi:10.2741/1224
  16. Fueger, 2010, Correlation of 6–18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas, J Nucl Med, 51, 1532, 10.2967/jnumed.110.078592 · DOI · Paper page
  17. Schiepers, 2007, 18F-FDOPA kinetics in brain tumors, J Nucl Med, 48, 1651, 10.2967/jnumed.106.039321 · DOI
  18. Becherer, 2003, Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine, Eur J Nucl Med Mol Imaging, 30, 1561, 10.1007/s00259-003-1259-1 · DOI · Paper page
  19. Chen, 2006, 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy, J Nucl Med, 47, 904
  20. Pöpperl, 2007, FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading, Eur J Nucl Med Mol Imaging, 34, 1933, 10.1007/s00259-007-0534-y · DOI · Paper page
  21. Pöpperl, 2006, Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?, J Nucl Med, 47, 393
  22. Lahoutte, 2004, SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation, J Nucl Med, 45, 1591
  23. Youland, 2013, The role of LAT1 in (18)F-DOPA uptake in malignant gliomas, J Neurooncol, 111, 11, 10.1007/s11060-012-0986-1 · DOI
  24. Kido, 2001, Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier, J Pharm Pharmacol, 53, 497, 10.1211/0022357011775794 · DOI
  25. del Amo, 2008, Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2, Eur J Pharm Sci, 35, 161, 10.1016/j.ejps.2008.06.015 · DOI · Paper page
  26. Shikano, 2003, Isoform selectivity of 3–125I-iodo-alpha-methyl-L-tyrosine membrane transport in human L-type amino acid transporters, J Nucl Med, 44, 244
  27. Weber, 2000, O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study, Eur J Nucl Med, 27, 542, 10.1007/s002590050541 · doi:10.1007/s002590050541
  28. Rau, 2002, O-(2-[(18)F]fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes, Eur J Nucl Med Mol Imaging, 29, 1039, 10.1007/s00259-002-0821-6 · DOI

Cited by

See all 133

Metadata

Authors
Kratochwil, C., Combs, S. E., Leotta, K., Afshar-Oromieh, A., Rieken, S., Debus, J., Haberkorn, U., & Giesel, F. L.
Venue
Neuro-Oncology
Published
2013-12-04
Volume
16
Issue
3
Pages
434-440
ISSN
  • 1523-5866
  • 1522-8517
Cited by
133
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. https://app.cochat.ai/papers/10.1093/neuonc/not199
The paper
Kratochwil, C., Combs, S. E., Leotta, K., Afshar-Oromieh, A., Rieken, S., Debus, J., Haberkorn, U., & Giesel, F. L. (2014). Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro-Oncology. https://doi.org/10.1093/neuonc/not199

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.